NextCure presents positive Phase 1 data for SIM0505 in gynecologic cancers
NextCure announced 55% objective response rate for SIM0505 in gynecologic cancers at ASCO 2026, with favorable safety in heavily pretreated patients. The data supports continued dose optimization and potential advancement toward pivotal trials for this CDH6-targeting antibody drug conjugate.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day